平安证券研报指出,百济神州2025年单三季度利润端实现盈利1.25亿美元,2025年前三季度公司实现盈利2.2亿美元(去年同期亏损4.93亿美元)。泽布替尼2025年单Q3全球销售额达10亿美元,前三季度全球实现收入27.8亿美元。公司在血液瘤领域全方位布局,BTK抑制剂泽布替尼全球放量迅速,此外,BCL2抑制剂、BTK CDAC在研推进顺利。公司通过快速概念验证持续丰富研发管线,在实体瘤领域、...
Source Link平安证券研报指出,百济神州2025年单三季度利润端实现盈利1.25亿美元,2025年前三季度公司实现盈利2.2亿美元(去年同期亏损4.93亿美元)。泽布替尼2025年单Q3全球销售额达10亿美元,前三季度全球实现收入27.8亿美元。公司在血液瘤领域全方位布局,BTK抑制剂泽布替尼全球放量迅速,此外,BCL2抑制剂、BTK CDAC在研推进顺利。公司通过快速概念验证持续丰富研发管线,在实体瘤领域、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.